2026– date –
-
Prime Medicine Secures NZ Clinical Trial Clearance for Prime Editing Therapy PM577a in H1069Q-Mutated Wilson Disease, Initiating Global Phase 1/2 Study
GlobeNewswire (Prime Medicine Press Release) USA Overview Prime Medicine has announced the approval of its Clinical Trial Application (CTA) in New Zealand for PM577a, an investigational prime editing therapy for H1069Q-mutated Wilson dis... -
Engineered Exosomes Breach Blood-Brain Barrier, Unlocking New Vistas in Neuro-Oncology
MDPI (論文) Global Overview The blood-brain barrier (BBB) critically impedes drug delivery to the brain, posing a major challenge for treating central nervous system diseases, particularly brain tumors. Engineered exosomes are emerging a... -
CAR-T Expands to Solid Tumors & Autoimmune Diseases; BAF CAR-T Shows Promising Early Results for Lupus, Compared with Off-the-Shelf CAR-NK Cells
University Hospitals USA Overview CAR-T cell therapy is expanding its success from hematologic malignancies to solid tumors and autoimmune diseases. Notably, early clinical trial results for BAF CAR-T in lupus are highly promising, sugge... -
Fate Therapeutics’ iPSC-Derived CAR-T FT836 Shows Early Phase 1 Data Suggesting Colorectal Tumor Shrinkage with Nine Engineered Edits
CRISPR Medicine News USA Overview Fate Therapeutics has announced initial Phase 1 data for FT836, an iPSC-derived, off-the-shelf CAR-T cell therapy. In a trial involving nine colorectal cancer patients, reductions in target lesion size a... -
CRISPR Medicine News Roundup: Sickle Cell CRISPR Drug Shows Potent Results in Young Children, Caribou’s Off-the-Shelf CAR-T Delivers Positive Phase 1 Data
CRISPR Medicine News USA Overview A CRISPR Medicine News summary article reports that the first approved CRISPR gene therapy for sickle cell disease demonstrated equally potent results in children as young as 5 years old. Additionally, C... -
Exosomes: Unlocking Nature’s Nanoparticles for Precision Medicine, Navigating Translational Hurdles
Frontiers (論文) Global Overview Exosome research is rapidly advancing, revealing substantial potential in drug delivery and regenerative medicine due to their inherent biocompatibility and targeting capabilities. However, clinical trans... -
Sartorius and LFB BIOMANUFACTURING Broaden Partnership to Offer Integrated Cell Line Development-to-GMP Services
PharmaSource Global Overview Sartorius and LFB BIOMANUFACTURING have expanded their strategic collaboration to provide integrated services spanning cell line development to GMP drug substance manufacturing. This partnership aims to simpl... -
Minaris Expands GMP Cell Banking Capabilities in Philadelphia, Enhancing Cell & Gene Therapy CDMO Services
Contract Pharma USA Overview Minaris has significantly enhanced its GMP cell banking suite at its Philadelphia facility, expanding its cell and gene therapy (CGT) CDMO services. This upgrade enables comprehensive support for clinical and... -
Beam Therapeutics Gains FDA IND Approval for In Vivo Base Editing Therapy BEAM-304 for PKU
CRISPR Medicine News USA Overview Beam Therapeutics has received U.S. FDA Investigational New Drug (IND) approval for BEAM-304, an in vivo base editing therapy targeting phenylketonuria (PKU). This therapy utilizes adenine base editing d... -
Automated Cell Therapy Manufacturing Lands $1.1 Billion Investment, Poised to Transform Commercialization and Patient Access
Tracxn (Indian Pharma Post経由) India Overview The automated cell therapy manufacturing sector has secured approximately $1.1 billion across 34 funding rounds, reflecting strong investor confidence and paving the way for scalable commerc...
